BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Flanagan DJ, Woodcock SA, Phillips C, Eagle C, Sansom OJ. Targeting ligand-dependent wnt pathway dysregulation in gastrointestinal cancers through porcupine inhibition. Pharmacology & Therapeutics 2022;238:108179. [DOI: 10.1016/j.pharmthera.2022.108179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Boudou C, Mattio L, Koval A, Soulard V, Katanaev VL. Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1045102] [Reference Citation Analysis]
2 Phillips C, Bhamra I, Eagle C, Flanagan E, Armer R, Jones CD, Bingham M, Calcraft P, Edmenson Cook A, Thompson B, Woodcock SA. The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand–dependent Cancer Models. Cancer Research Communications 2022;2:914-928. [DOI: 10.1158/2767-9764.crc-21-0095] [Reference Citation Analysis]